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Dural arteriovenous fistulas (DAVFs) account for approximately 10% of all intracranial shunts in children.9 DAVFs are direct arteriovenous con-
nections in the dura, with drainage into dural sinuses or 
pial cortical veins. Although these rare lesions can be con-
genital, some studies suggest that many are acquired.9,24 
The natural history of DAVFs in neonates and children 
has become better known over the last several decades. 
Untreated lesions can lead to potentially fatal high-output 
cardiac failure as well as severe and irreversible neurode-
velopmental delay.1,5,6,9–15,21,24 Endovascular embolization 
is the primary treatment for DAVFs.3,7,24
In this paper we present one of the largest single-insti-
tution experiences with management of pediatric DAVFs. 
We compare clinical presentations, angioarchitecture, and 
treatment outcomes of neonates and infants with DAVFs 
presenting in the first year of life with those of children 
presenting later in life (between the ages of 1 and 18 years). 
abbreviations AVM = arteriovenous malformation; CCA = common carotid artery; CHF = congestive heart failure; CI = confidence interval; DAVF = dural arteriovenous 
fistula; DSA = digital subtraction angiogram; DSM = dural sinus malformation; mRS = modified Rankin Scale; NGAVF = non-Galenic pial arteriovenous fistula; OR = odds 
ratio; SSS = superior sagittal sinus; VOGM = vein of Galen malformation.
sUbMitteD December 26, 2015. accePteD May 24, 2016.
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obJective Intracranial dural arteriovenous fistulas (DAVFs) are rare in children. This study sought to better character-
ize DAVF presentation, angioarchitecture, and treatment outcomes.
MethoDs Children with intracranial DAVFs between 1986 and 2013 were retrospectively identified from the neuroin-
terventional database at the authors’ institution. Demographics, clinical presentation, lesion angioarchitecture, treatment 
approaches, angiographic outcomes, and clinical outcomes were assessed.
resUlts DAVFs constituted 5.7% (22/423) of pediatric intracranial arteriovenous shunting lesions. Twelve boys and 
10 girls presented between 1 day and 18 years of age; boys presented at a median of 1.3 years and girls presented at 
a median of 4.9 years. Four of 8 patients ≤ 1 year of age presented with congestive heart failure compared with 0/14 
patients > 1 year of age (p = 0.01). Five of 8 patients ≤ 1 year old presented with respiratory distress compared with 0/14 
patients > 1 year old (p = 0.0021). Ten of 14 patients > 1 year old presented with focal neurological deficits compared 
with 0/8 patients ≤ 1 year old (p = 0.0017). At initial angiography, 16 patients harbored a single intracranial DAVF and 6 
patients had 2–6 DAVFs. Eight patients (38%) experienced DAVF obliteration by the end of treatment. Good clinical out-
come (modified Rankin Scale score 0–2) was documented in 77% of patients > 1 year old at presentation compared with 
57% of patients ≤ 1 year old at presentation. Six patients (27%) died.
conclUsions Young children with DAVFs presented predominantly with cardiopulmonary symptoms, while older chil-
dren presented with focal neurological deficits. Compared with other pediatric vascular shunts, DAVFs had lower rates of 
angiographic obliteration and poorer clinical outcomes.
http://thejns.org/doi/abs/10.3171/2016.5.PEDS15740
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Finally, we compare the outcomes of children with DAVFs 
with other pediatric intracranial arteriovenous shunts.
Methods
study cohort
In this institutional review board–approved study, a 
neurointerventional database was used to identify a cohort 
of 423 patients ≤ 18 years of age who had undergone eval-
uation and treatment for intracranial arteriovenous shunts 
at our hospital between 1986 and 2013. Medical records 
and imaging reports were reviewed. Forty patients with 
potential DAVFs were identified. Patients who developed 
DAVFs subsequent to treatment of another primary intra-
cranial arteriovenous shunting lesion (e.g., non-Galenic 
pial arteriovenous fistula [NGAVF] or arteriovenous mal-
formation [AVM]) were excluded. After further review of 
reports, the cohort was reduced to 24 patients with pri-
mary intracranial DAVFs. Of these 24 patients, 2 were ex-
cluded due to insufficient clinical or imaging data.
Medical record review
Baseline clinical presentation data were collected for 
each subject (Supplemental Table 1). Arterial and venous 
angioarchitectural characteristics identified from initial 
pretreatment angiograms were also documented (Supple-
mental Tables 2 and 3).
imaging review
Baseline cerebral digital subtraction angiograms 
(DSAs) with corresponding reports were available for 
20 of 22 patients. Angiographic images were reviewed 
and scored (by S.W.H., N.M., and P.M.) according to a 
structured angiographic data collection tool originally 
developed for brain AVMs and subsequently modified to 
highlight features specific to DAVFs.4,17 If discrepancies 
between angiographic images and reports were discov-
ered, images were reviewed and results derived from im-
age review were used for final scoring. Two patients were 
scored from structured angiographic reports alone due to 
an inability to retrieve old images. These reports are of 
the same format and were authored by the same group of 
angiographers present for the entire study period. To ex-
clude potential bias from inclusion of the aforementioned 
2 patients, we performed a sensitivity analysis on data ex-
cluding these patients and did not find significant changes 
in effect sizes (data not shown).
TABLE 1. Clinical presentation and fistula angioarchitecture stratified by age at presentation 
Baseline Clinical Characteristics All Patients Age ≤1 Yr Age >1 Yr OR 95% CI p Value*
No. of patients 22 8 14
Age
 Mean ± SD 6.8 ± 7.7 yrs 108 ± 122 days 10.5 ± 7.4 yrs
 Median 1.7 yrs 92 days 11.6 yrs 
 Range 1 day–18.9 yrs 1–353 days 1.2–18.9 yrs
Males (%) 12 (55) 5 (63) 7 (50) 1.7 0.21–15 0.67
Seizures (%) 3 (14) 1 (13) 2 (14) 0.86 0.13–20 1
CHF (%) 4 (18) 4 (50) 0 (0) Inf 2.8–inf 0.01
Headaches (%) 2 (9) 0 (0) 2 (14) 0 0–3.4 0.52
Focal neurological deficit (%) 10 (45) 0 (0) 10 (71) 0 0–0.25 0.0017
Hydrocephalus (%) 7 (32) 6 (75) 1 (7) 39 2.2–1900 0.0023
Respiratory distress (%) 5 (23) 5 (63) 0 (0) Inf 4.4–inf 0.0021
Current or prior hemorrhage (%) 4 (18) 2 (25) 2 (14) 2 0.11–33 0.6
Trauma (%) 3 (14) 0 (0) 3 (22) 0 0–2.1 0.27
Any identified comorbidity or risk factor (%) 18 (82) 7 (88) 11 (79) 1.9 0.12–110 1
Angioarchitecture (%)
 >1 DAVF 5 (23) 1 (13) 4 (29) 0.36 0.0064–5 0.61
 >1 arteriovenous connection 15 (68) 6 (75) 9 (64) 1.7 0.18–23 1
 >10 arteriovenous connections 5 (23) 3 (38) 2 (14) 3.6 0.29–53 0.31
 Additional vascular lesions (non-DAVF) 4 (18) 2 (25) 2 (14) 2 0.11–33 0.6
 Venous ectasia/varix 11 (50) 5 (63) 6 (43) 2.2 0.28–20 0.66
 Venous reflux 11 (50) 3 (38) 8 (57) 0.45 0.051–3.6 0.66
 Venous sinus thrombus/occlusion 13 (59) 6 (75) 7 (50) 3 0.34–39 0.38
 Pseudophlebitic cortical venous pattern 8 (36) 1 (13) 7 (50) 0.14 0.0028–1.8 0.17
 Venous sinus dilation 12 (55) 6 (75) 6 (43) 4 0.45–51 0.2
 Persistent fetal venous structures 6 (27) 4 (50) 2 (14) 6 0.54–83 0.14
Inf = infinite. 
* p values derived from Fisher’s exact test.
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DAVFs were categorized into those with single arterio-
venous connections and those with multiple arteriovenous 
connections. Venous sinus dilation was defined as twice 
the expected diameter of a given dural venous sinus based 
on angiograms performed at our institution of children of 
similar ages but without arteriovenous shunting. Venous 
reflux was defined as any abnormal reversal of blood flow 
within cerebral veins or venous sinuses on DSAs. Pseudo-
phlebitic cortical venous pattern was defined as tortuous, 
engorged pial veins noted during the venous phase of digi-
tal subtraction angiography.
treatment
Patients were managed with conservative observation, 
endovascular intervention, a combination of endovascular 
and surgical intervention, or a combination of endovascu-
lar and radiosurgical intervention. Treatment and outcome 
data are detailed in Supplemental Table 4.
outcomes
Two investigators (S.W.H. and N.M.) reviewed medi-
cal records from each patient’s last available clinical 
follow-up evaluation to assess neurological status and de-
velopmental disability; any disagreements were resolved 
via further review and consensus. An adapted modified 
Rankin Scale (mRS) score of neurological disability28 for 
pediatric patients with brain AVMs was used to retrospec-
tively assign each patient both baseline clinical function 
and final clinical function. Good clinical outcome was de-
fined as pediatric mRS scores of 0–2. Images and imaging 
reports from each patient’s last follow-up were evaluated 
for residual arteriovenous shunting or new DAVF forma-
tion. Follow-up duration was calculated from initial clini-
cal presentation to final clinical or imaging report.
statistical analysis
Our cohort of patients was stratified both by sex and 
age at presentation: neonates and infants presenting at ≤ 1 
year of age compared with older children presenting at > 
1 year of age (Tables 1 and 2). Student t-tests were used to 
compare continuous normally distributed data, Wilcoxon 
rank-sum (Mann-Whitney) tests were used to compare or-
dinal data, and Fisher’s exact tests were used to compare 
proportions. Descriptive statistics and t-tests were calcu-
lated using Excel for Macintosh 2011 (Microsoft). Odds 
ratios (ORs), confidence intervals (CIs), Fisher’s exact 
tests, and Wilcoxon rank-sum tests were calculated using 
Stata SE (version 12.1, StataCorp).
TABLE 2. Treatments and outcomes stratified by age at presentation 
Treatments All Patients Age ≤1 Yr Age >1 Yr OR 95% CI p Value*
Age at first treatment
 Mean ± SD 6.8 ± 7.7 yrs 108 ± 122 days 10.5 ± 7.4 yrs 0.0009
 Median 1.7 yrs 92 days 11.6 yrs 
 Range 1 day–18.9 yrs 1 day–353 days 1.2–18.9 yrs
Median Dx or Tx procedures (range) 2 (1–19) 1 (1–5) 2 (1–19) 0.42†
Median treatment procedures (range) 1 (0–18) 1 (0–5) 2 (1–18) 0.22†
Endovascular treatments only 14/21 (67%) 5/8 (63%) 9/13 (69%) 0.74 0.83–7.3 1
Any open surgical treatment 4/21 (19%) 1/8 (13%) 3/13 (23%) 0.48 0.0080–7.7 1
Any stereotactic radiosurgery 2/21 (10%) 0/8 (0%) 2/13 (15%) 0 0–3.2 0.5
Observation only 2/21 (10%) 2/8 (25%) 0/13 (0%) Inf 0.93–inf 0.13
Procedural or periprocedural complication 4/21 (19%) 1/8 (13%) 3/13 (23%) 0.48 0.0080–7.7 1
Outcomes at last follow-up
 Follow-up duration‡
  Mean ± SD 5.5 ± 6.3 yrs 3.5 ± 5.7 yrs 6.4 ± 6.5 yrs 0.37
  Median 3.6 yrs 186 days 6.1 yrs 
  Range 2 days–23.1 yrs 2 days–14.2 yrs 180 days–23.1 yrs
 Elimination of all arteriovenous shunting 8/21 (38%) 3/8 (38%) 5/13 (38%) 1 0.12–8.9 1
 White matter calcifications§ 2/11 (18%) 0/5 (0%) 2/6 (33%) 0 0–2.2 0.45
 Normal neurological examination¶ 6/16 (38%) 1/5 (20%) 5/11 (45%) 0.3 0.0051–4.9 0.59
 Deceased after discharge for any reason 6/22 (27%) 2/8 (25%) 4/14 (29%) 0.83 0.059–8.2 1
 Median last mRS score (range)** 1 (0–6) 1 (0–6) 1 (0–6) 0.53†
 Good outcome (last mRS score 0–2)** 14/20 (70%) 4/7 (57%) 10/13 (77%) 0.4 0.037–4.5 0.61
Dx = diagnostic, Tx = therapeutic. 
* p values are derived from Fisher’s exact test unless otherwise specified.
† Wilcoxon log rank-sum test.
‡ Data available for 18/22 patients. 
§ Data available for 11/22 patients. 
¶ Data available for 16/22 patients. 
** Data available for 20/22 patients. 
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results
Demographic information
DAVFs were present in 5.7% (24/423) of the pediatric 
patients evaluated and treated for intracranial arteriove-
nous shunts at our hospital during the study period. Of the 
22 patients included for further analysis, 8 presented at ≤ 
1 year of age and 14 presented at > 1 year of age (median 
age 1.7 years, range 1 day to 18.9 years; Table 1). Whereas 
12 boys presented at a median age of 1.3 years, 10 girls 
presented at a median of 4.9 years. Detailed baseline de-
mographics and clinical presentations are summarized in 
Supplemental Table 1.
clinical Presentation
Clinical presentation varied by age (Table 1) but was 
not significantly different between boys and girls. One boy 
was suspected to have an intracranial arteriovenous fis-
tula on fetal MRI in the setting of hydrops fetalis. Three 
patients presented as neonates (< 1 month), 5 patients pre-
sented in later infancy (3 months to 1 year), and 14 patients 
presented later in childhood (1.2–18 years).
Neonates presented with congestive heart failure (CHF; 
3/3), respiratory distress (2/3), and hydrocephalus (3/3). 
Aside from hypotonia (3/3), neurological deficits were not 
apparent in this very young group. No intracranial hem-
orrhages were identified in this group. Of 5 patients who 
presented between 1 month and 1 year of age, 3 had respi-
ratory distress, 3 had hydrocephalus or macrocephaly, 2 
had facial or cranial hemangiomas or venous or lymphatic 
malformations, 1 had seizures, 1 had developmental delay, 
and 2 had intracranial hemorrhage.
Of 14 patients who presented after the first year of life, 
clinically 2 children presented with headaches, 2 demon-
strated developmental delay, 2 presented with intracranial 
hemorrhage, and 3 children presented with carotid cavern-
ous fistulas following trauma. On examination, 10 present-
ed with focal neurological deficits (cranial nerve palsies, 
aphasia, hemiparesis, axial weakness, facial droop, and 
ophthalmoplegia), 6 had cranial bruits, 2 demonstrated 
head and neck hemangiomas or venous or lymphatic mal-
formations, and 1 child was macrocephalic with hydro-
cephalus.
Potential risk factors for intracranial DAVFs as well as 
comorbidities associated with significant arteriovenous 
shunting were identified in multiple patients. One patient 
had hydrops fetalis due to severe arteriovenous shunting. 
Obstetric complications that may have contributed to fe-
tal CHF included maternal diabetes mellitus Type 2 and 
placental abruption. One patient had Cowden syndrome. 
Several patients possessed congenital vascular anomalies 
including a forehead angioma, eyelid and scalp hemangio-
mas, a lymphatic malformation of the neck and tongue, 
and a port wine stain.
angioarchitecture
DAVF angioarchitecture in our cohort did not vary 
significantly between different age groups (Table 1). 
Identification of multiple DAVFs (between 2 and 6) in a 
single patient occurred in 29% of the patients > 1 year 
old versus 13% of patients ≤ 1 year old (p = 0.61). Both 
age groups demonstrated similar proportions of patients 
with complex DAVFs possessing more than 1 arteriove-
nous connection. Common DAVF locations included the 
torcula (n = 9), transverse sinus (n = 7), superior sagittal 
sinus (SSS; n = 6), and cavernous sinus (n = 6). With re-
gard to vascular sequelae of dural arteriovenous shunting, 
venous sinus dilation trended toward occurring more fre-
quently in younger children (75% vs 43%, respectively; p 
= 0.2) but both age groups possessed similar percentages 
of patients with venous ectasia, venous reflux, and venous 
sinus thrombosis. A pseudophlebitic cortical venous pat-
tern secondary to venous congestion was observed more 
commonly in patients > 1 year of age (50%) as compared 
with patients ≤ 1 year of age (13%; p = 0.17). Significant 
differences in DAVF angioarchitecture were not observed 
between the male and female patients, although there was 
a trend toward venous reflux occurring more commonly 
in girls (p = 0.2).
treatment
Treatments, imaging outcomes, clinical outcomes, and 
procedural complications are detailed in Table 2 and Sup-
plementary Table 4. Patients received between 1 and 19 
endovascular, radiosurgical, or surgical procedures with a 
median of 2 interventions. Sixty-seven percent of our pa-
tients received endovascular treatment only. Patients pre-
senting at > 1 year of age trended toward more treatments 
than patients presenting at ≤ 1 year (median 2 vs median 
1, p = 0.22).
Twenty-one of 22 patients had sufficient data available 
at our institution with regard to DAVF treatment and were 
further analyzed. Transvenous and transarterial endovas-
cular treatments employed a variety of materials: coils, 
11/21 patients (52%); particulate embolics, 8/21 patients 
(38%); liquid adhesives, 8/21 patients (38%); absolute etha-
nol, 3/21 patients (14%); detachable balloons, 3/21 patients 
(14%); and silk sutures, 1/21 patients (5%). Four patients 
(19%) underwent craniotomy and resection and 2 patients 
table 3. comparison of pediatric DavF outcomes in the 
literature
Outcome
Current 
Study (%)
Kincaid et al., 
2001 (%)
Walcott et al., 
2013 (%)
Complete AVF occlusion 8/21 (38) 3/7 (43) 6/7 (86)
No neurological deficit or 
developmental delay
7/20 (35) 2/7 (29) 7/7 (100)
Death 6/22 (27) 2/7 (29) 0/7 (0)
table 4. outcomes among different pediatric intracranial avFs 
at our institution
Outcome
DAVF Current 
Study (%)
NGAVF 
201117 (%)
VOGM 
20038 (%)
Complete AVF occlusion 8/21 (38) 15/23 (65) 21/27 (78)
No neurological deficit or 
developmental delay
7/20 (35) 11/23 (48) 14/27 (52)
Death 6/22 (27) 2/23 (9) 4/27 (15)
s. w. hetts et al.
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(10%) underwent stereotactic radiosurgery following em-
bolization.
Procedural or periprocedural complications occurred 
in 4 of 21 patients (19%), in patients 204 days, 1.3 years, 2 
years, and 9.6 years old. Complication rates did not differ 
between patients ≤ 1 year of age and patients > 1 year of 
age or between male and female patients. Complications 
included access-site femoral artery stenosis following em-
bolization, postoperative craniotomy infection following 
resection, catheter-induced vasospasm requiring intraar-
terial verapamil infusion, and nontarget coil embolization 
to the lungs with subsequent endovascular coil recovery.
imaging and clinical outcomes
Mean follow-up was 5.5 ± 6.3 years with a median of 
3.6 years and range of 2 days to 23.1 years. Eight (38%) 
of 21 patients with complete imaging data demonstrated 
angiographic elimination of arteriovenous shunting at last 
imaging follow-up. Elimination of arteriovenous shunting 
was achieved at similar rates (38%) in patients ≤ 1 year 
of age and patients > 1 year of age. Girls had higher rates 
of arteriovenous shunting elimination (50%) as compared 
with boys (27%), although this difference was not signifi-
cant (p = 0.38). Patients who presented at age > 1 year 
and female patients more often demonstrated imaging se-
quelae of “melting brain syndrome” such as cerebral white 
matter calcifications, which is likely a result of chronic 
venous hypertension secondary to arteriovenous shunting 
(2/6 vs 0/5, respectively), but these differences also did not 
reach significance (p = 0.45).
Clinical outcomes did not vary significantly between 
age groups or by sex. The median mRS score at last fol-
low-up for all surviving patients was 1. Male and female 
patients both demonstrated a median mRS score of 1 at 
last follow-up, as did patients who presented at ≤ 1 year 
and those who presented at > 1 year. Good clinical out-
come (pediatric mRS score of 0–2 at last clinical follow-
up) was documented in 10/13 patients > 1 year of age at 
presentation as compared with 4/7 patients ≤ 1 year of age 
at presentation (p = 0.61). At last follow-up, 6/22 patients 
(27%) were deceased: 2 neonates died within 1 week of 
treatment and 4 older children died after a delay of several 
years, including 1 who died of recurrent leukemia and the 
others as a sequelae of the DAVF.
Whereas 6/11 patients (55%) with venous reflux had 
poor outcomes (pediatric mRS score 3–6), all 10 patients 
without venous reflux had good outcomes (pediatric mRS 
score 0–2, p = 0.01). There was also a more frequent asso-
ciation between venous reflux and poor outcomes among 
boys (5/6, 83%) versus girls (1/5, 20%, p = 0.08). Three 
(43%) of 7 patients with torcular involvement had poor 
outcomes. There was no significant difference in out-
comes in the presence of venous reflux between patients ≤ 
1 year of age (3/3, 100%) compared with patients > 1 year 
of age (3/8, 37%, p = 0.18), which may be related to the 
small number of patients with this rare disease.
Discussion
DAVFs are defined by an aberrant connection between 
a dural artery and either a dural venous sinus or cortical 
vein. The complexity of these lesions can vary substan-
tially, with some DAVFs having only a single arteriove-
nous connection and others having numerous arteriove-
nous connections. Although pediatric DAVFs may arise 
early in utero, analogous to a vein of Galen malformation 
(VOGM), some of these lesions appear to be acquired 
later in development or postnatally. The presence of ma-
ture arterial and venous architecture in most DAVFs, for 
example, suggests that DAVFs are most likely acquired 
at some point following the third month of intrauterine 
life. Massive venous sinus enlargement is a hallmark of 
congenital DAVFs not observed in adult-acquired DAVFs, 
underscoring their origins in the fetus wherein sinuses are 
normally large and may remain large due to high fistu-
lous flow, instead of regressing. It is theorized that venous 
thrombosis during fetal life promotes the formation of 1 
or more DAVFs prior to birth, analogous to venous sinus 
thrombosis in adults leading to DAVF formation.9 Postna-
tally, however, thrombocytopenia due to platelet consump-
tion along the surface of huge clots in enlarged venous 
sinuses can complicate DAVF treatment.22
There are two major hypotheses explaining the patho-
genesis of DAVFs. One hypothesizes that DAVFs arise 
from “dormant” channels between the external carotid 
circulation and the venous pathways within the dura mater 
that open in response to venous hypertension.2,19 The other 
suggests that new vascular channels are stimulated by an-
giogenic factors that arise directly from sinus thrombosis 
or as a result of tissue hypoxia.16,26,27,29,30,32 Although the 
etiology of DAVFs remains to be elucidated, it is likely that 
the combination of arterialized turbulent blood, progres-
sive venous sinus stenosis/hypertension, and venous reflux 
results in progressive veno-occlusive disease that can lead 
to the melting brain syndrome, as noted in several of our 
patients (Fig. 1). In the melting brain syndrome, chron-
ic venous hypertension leads to irreversible brain injury 
with white matter calcifications and encephalomalacia. 
Usually bilateral and symmetric, melting brain syndrome 
corresponds to a regional decrease in cerebral blood flow 
caused by the retrograde venous hypertension.22
Risk factors for development of DAVFs may be genetic 
or environmental. Some arteriovenous shunts have been 
linked to chromosomal abnormalities, including hemor-
rhagic hereditary telangiectasia and neurofibromatosis 
Type I (as in Case 7 in our cohort; Supplemental Table 
1).20,22,29 Many of our patients with DAVFs also present-
ed with peripheral hemangiomas or venous or lymphat-
ic malformations. Hypercoaguable states are also a risk 
factor for sinus thrombosis and subsequent formation of 
DAVFs, including leukemia (Case 17, Fig. 2; Supplemental 
Table 1) and smoking. Trauma—as in Cases 18, 20, and 
22—is another well-known risk factor for the development 
of DAVFs.
We identified 24 patients with imaging-confirmed 
DAVFs from a cohort of 423 patients with intracranial 
arteriovenous shunts, for a total incidence of 5.7%. This 
is lower than the incidence of approximately 10% re-
ported by Garcia-Monaco et al.9 The true incidence of 
this rare disease is unknown. Five (23%) of 22 patients 
in our cohort had multiple separate (multifocal) DAVFs 
as compared with 3.5% of patients in the Garcia-Monaco 
Pediatric dural arteriovenous fistulas
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series.9 In contrast to the Kincaid et al.21 and Garcia-Mo-
naco9 DAVF series, in our study multifocal DAVFs were 
observed more often in patients > 1 year of age at presen-
tation as compared with patients ≤ 1 year of age. Some 
of this may be due to the high complexity and size of the 
3 neonatal DAVFs in our series. For example, in Case 3 
(Supplemental Table 2), it was difficult to judge whether 
that patient had a single large torcular DAVF or instead 
had adjacent but separate torcular and superior vermian 
DAVFs.
Our data suggest that neonates and infants up to 1 year 
of age predominantly present with cardiorespiratory symp-
toms from high-output arteriovenous shunting and under-
resorption hydrocephalus due to intracranial venous hy-
pertension. Older patients tended to present with neurolog-
ical symptoms as opposed to cardiorespiratory symptoms. 
Younger children more commonly presenting with CHF, 
respiratory distress, and hydrocephalus, and older children 
more commonly presenting with focal neurological defi-
cits is consistent with other pediatric DAVF series9,21,24 and 
also parallels the clinical presentations in NGAVF17 and 
VOGM.23 As with adults, the most predictive feature for 
future neurological manifestations was the presence or ab-
sence of cerebral venous reflux.6 In our analysis, more than 
half of patients with venous reflux had poor outcomes. All 
patients without venous reflux had good outcomes.
With regard to DAVF location, our results were similar 
to those in other major series with the most common sites 
being the torcula, SSS, transverse sinus, and cavernous 
sinus (Fig. 3).9,21,24 DAVFs away from the torcula should 
theoretically have a better chance of favorable outcomes, 
as there will be at least 1 normal sinus for the brain to 
drain. In our series, 43% of patients with torcular involve-
ment had poor outcomes.
Multiple classification systems exist for pediatric 
DAVFs. Lasjaunias’ classification system included 3 types 
of shunts, including the dural sinus malformation (DSM), 
infantile-type DAVFs, and adult-type DAVFs.24 DSMs can 
further be subdivided into 2 types. The first type of DSM 
involves the posterior sinus with or without the torcula, 
with giant dural lakes and slow-flow mural arteriovenous 
shunting. Spontaneous thrombosis may further restrict 
cerebral venous drainage and subsequently lead to intra-
parenchymal hemorrhagic infarction. The second type of 
DSM involves the jugular bulb with otherwise normal si-
nuses but associated with a high-flow sigmoid sinus AVF. 
The prognosis is excellent with embolization treatment.24 
In our series, there were 4 patients with DSMs, 2 died dur-
ing the study, and 2 met their respective developmental 
milestones (ages 4 months and 16 years).
Infantile dural arteriovenous shunts are high flow and 
low pressure. The sinuses are large and patent with no 
lakes. Clinical onset is observed in the first few years of 
life and the shunts are initially well tolerated. Progressive 
symptoms (symptoms of raised intracranial pressure and 
venous ischemia) develop at a later age and initially re-
Fig. 1. Case 4. Imaging in this patient demonstrated extensive multifocal high-risk DAVFs involving the torcula and left transverse 
sinus, as shown on the axial T1-weighted MR image (a), coronal T2-weighted MR image (b), arterial phase right common carotid 
artery (CCA) angiogram (anteroposterior projection; c), and venous phase right CCA angiogram (anteroposterior projection; D). 
The initial axial CT scan demonstrated no evidence of calcifications (e). The long-term follow-up CT scan demonstrated melting 
brain syndrome, including calcifications and encephalomalacia in the setting of chronic venous hypertension related to the incom-
pletely treated extensive multifocal high-risk DAVF (F).
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spond to partial embolization. The long-term prognosis is 
poor with neurological deterioration in early adulthood.24 
In our series, there were a total of 6 patients with infantile-
type DAVFs (1 child demonstrating both infantile- and 
adult-type fistulas). On last follow-up only 1 child was 
meeting their developmental milestones. Two of the chil-
dren were deceased, 1 had a poor neurological examina-
tion result, and the other 2 required special assistance.
Adult-type DAVFs are present in all age groups and al-
most all of them are located in the cavernous venous plex-
us. Post-embolization outcome is excellent.24 In our series, 
10 patients demonstrated adult-type DAVFs and all but 1 
were meeting their respective developmental milestones (1 
child was deceased due to leukemia).
Endovascular intervention is the mainstay of DAVF 
treatment.21 Surgery and radiosurgery are usually reserved 
for cases in which endovascular therapy fails or is not pos-
sible due to difficult access to the fistula site. We favor the 
use of coils to treat DAVFs in young children over the use 
of liquid embolic agents, given the potential for nontarget 
embolization of liquid embolics to the lung or elsewhere. 
Close collaboration with pediatric cardiology is essential, 
not only for evaluation of right-to-left shunting, raising the 
potential for systemic nontarget embolization, but also for 
evaluation of DAVF treatment effect on CHF. Nontarget 
embolization of liquid embolic agents in neonates and in-
fants, especially in the setting of CHF, can be clinically 
devastating. Nontarget embolization of coils to the lungs 
can also occur, but coils are potentially retrievable. In 
some cases performing embolization solely with coils is 
Fig. 2. Case 17. Neuroimaging in this patient demonstrated DAVF formation following SSS thrombosis. The axial contrast-
enhanced CT scan shows SSS thrombosis (a). An external carotid artery angiogram (arterial phase, lateral projection) is given 
(b), and the external carotid artery angiogram venous phase, lateral projection (c) demonstrates pseudophlebitic venous drainage 
(arrowheads).
Fig. 3. Case 2. Neonate with CHF and massive torcular DAVF. a: Axial T2-weighted MRI. b: Sagittal T1-weighted MRI. c: MR 
venogram, anteroposterior projection. D: MR venogram, lateral projection. e: CCA angiogram, anteroposterior projection. F: 
Vertebral artery angiogram, lateral projection, demonstrating the torcular DAVF with multiple feeders.
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unrealistic and a combination of coils and liquid embolic 
agents are needed to stop flow at the fistulous point. With 
the introduction of ethylene vinyl copolymer, several re-
ports both in children and adults have demonstrated suc-
cessful results with acceptable complication rates.6,31 The 
relatively long time over which ethylene vinyl copolymer 
is deposited, however, leads to relatively high fluoroscopy-
related x-ray doses.
Despite advances in embolization techniques, endovas-
cular treatment of pediatric DAVFs remains challenging. 
The neurointerventionalist must account for the presence 
of high-flow fistulas, tortuous intracranial feeding arter-
ies, a small femoral artery access site, limitations in the 
volume of contrast, and risk of general anesthesia in a 
critically ill neonate. Due to small total blood volumes and 
coexistent CHF, surgery is also risky in neonates. Stereo-
tactic radiosurgery has limited ability to induce regression 
of large caliber fistulas, and from a practical standpoint, 
frame placement is not possible in young patients with 
open cranial sutures. Our overall approach for the treat-
ment of DAVFs is similar to our approach to other pedi-
atric vascular shunts (NGAVFs, VOGMs).8,23 We favor 
delaying treatment until after the first several months of 
life unless CHF or signs of venous hypertension neces-
sitate early intervention. Due to the significant morbidity 
and mortality associated with these lesions and possibility 
of recruitment of secondary shunts, our goal is to eradicate 
the fistula site. However, as noted by Kincaid et al.,21 com-
plex multifocal dural shunts cannot be immediately cured 
by current embolization techniques because complete oc-
clusion of all the involved sinuses would result in severe 
venous outflow restriction. In patients with complex multi-
focal DAVFs, endovascular treatment is staged with peri-
ods of observation generally aimed at symptomatic relief.
At the last clinical or imaging follow-up evaluation, 
8/21 patients (38%) in our cohort demonstrated complete 
elimination of arteriovenous shunting, 7/20 (35%) had no 
neurological deficit or developmental delay, and 6/22 pa-
tients (27%) were deceased. Kincaid et al.21 reported elimi-
nation of arteriovenous shunting in 3/7 patients (43%), no 
neurological deficit or developmental delay in 2/7 patients 
(29%), and death in 2/7 patients (29%). On the other hand, 
Walcott et al.33 reported elimination of arteriovenous 
shunting in nearly all their patients (6/7, 86%), no neuro-
logical deficit or developmental delay in any of their pa-
tients (7/7, 100%), and no deaths (Table 3). Treatment in 
the Kincaid et al. and Walcott et al. series was almost ex-
clusively endovascular, with 1 exception in the Walcottt et 
al. series that used combined endovascular/surgical treat-
ment. The Walcott et al. study concluded that treatment 
is effective in the obliteration of DAVFs in children and 
is well tolerated, with patients having excellent prognoses. 
Most of the children in that series were older and were 
stable clinically on presentation. Our study and the Kin-
caid group, however, include more neonates and infants 
who were less stable clinically on presentation. Further-
more, the Walcott et al. study did not report the complex-
ity and angioarchitecture of their DAVFs, making direct 
comparisons difficult. The similarity between results from 
our center and the Kincaid group suggests that DAVF re-
mains a challenging diagnosis to treat in children. In their 
long-term experience with pediatric DAVFs, Lasjaunias et 
al.25 noted that some DAVFs are lethal even 10 years after 
onset, indicating the caution with which we must approach 
our decisions. Long-term follow-up should contextualize 
optimistic case reports about these lesions.25
Compared with other pediatric intracranial AVF pa-
tient groups studied at our institution, our DAVF cohort 
had lower rates of complete AVF occlusion, lower rates 
of children with no neurological deficit or developmental 
delay at last clinical follow-up, and higher rates of death 
at last known follow-up (Table 4).8,17 It is also sobering to 
note that patients with DAVFs presenting in childhood 
are more likely to have de novo formation of additional 
DAVFs later in life.18
conclusions
Similar to other intracranial arteriovenous shunting le-
sions in children, DAVFs are more likely to present with 
cardiorespiratory distress and hydrocephalus in neonates 
and infants ≤ 1 year of age and with focal neurological 
deficits in patients > 1 year of age. Given the complex an-
gioarchitecture of these lesions, morbidity of these lesions 
remains high. Long-term outcomes are generally worse 
for children with DAVFs as compared with other types of 
intracranial arteriovenous fistulas. If symptomatic, treat-
ment appears warranted to prevent the long-term sequelae 
of venous hypertension.
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